Jounce Gets $47M Series A, Seeks to Jolt Cancer Therapy
Third Rock Ventures LLC plumbed its considerable network and assembled a team of prestigious cancer biologists and immunotherapy experts to form Jounce Therapeutics Inc., which launched Thursday with a $47 million Series A financing.
Based in Cambridge, Mass., the company will seek to discover and develop first-in-class cancer immunotherapies in a space that has drawn enormous interest since the FDA approvals of immune-stimulating targeted therapeutics Provenge (sipuleucel-T, Dendreon Inc.) and Yervoy (ipilimumab, Bristol-Myers Squibb Co.).
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter